BETTER OUTCOME OF HIGH-DOSE CEFTAZIDIME IN HEMATO – ONCOLOGICAL PATIENTS WITH INFECTIONS CAUSED BY EXTENSIVELY DRUG-RESISTANT PSEUDOMONAS AERUGINOSA
-
Published:2022-12-31
Issue:1
Volume:15
Page:e2023001
-
ISSN:2035-3006
-
Container-title:Mediterranean Journal of Hematology and Infectious Diseases
-
language:
-
Short-container-title:Mediterr J Hematol Infect Dis
Author:
Zavrelova Alzbeta,Radocha Jakub,Paterova Pavla,Zak Pavel,Visek Benjamin,Sima Martin
Abstract
Background: P. aeruginosa sepsis in immunocompromised patients is serious complication of cancer treatment, especially in case of XDR pathogen.
The purpose of the study is to evaluate the efficacy of high-dose ceftazidime in treatment of XDR P. aeruginosa infection and to compare it with the conventionally treated cohort in hemato-oncological patients.
Methods: We identified 27 patients with XDR P. aeruginosa infection during the 2008-2018 period, 16 patients served as a conventionally treated cohort with antipseudomonal beta-lactam antibiotic in standard dose (cohort A), and 11 patients were treated with high-dose ceftazidime (cohort B). Most of the patients were neutropenic and under active treatment for their cancer in both cohorts.
Results: Mortality and related mortality were statistically significantly better for cohort B compared to cohort A, it was 18.2% and 9.1% for cohort B and 68.8% and 68.8% for cohort A, respectively. More patients in cohort A needed mechanical ventilation and renal replacement therapy, 75% and 50% for cohort A and 27.3% and 9.9% for cohort B, respectively. It corresponded well with the worst SOFA in cohort A in comparison to cohort B, 16 versus 7 respectively. Reversible neurotoxicity was seen only in two patients in cohort B.
Conclusion: Ceftazidime in high doses is a very potent ATB for the treatment of XDR P. aeruginosa infections in neutropenic cancer with acceptable toxicity.
Publisher
Hematology Section, Dept. of Radiological Science and Hematology, Catholic University, Rome, Italy
Subject
Infectious Diseases,Hematology
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献